Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

EMA committee recommends marketing approval of AVT06, Alvotech’s proposed biosimilar to Eylea: Reykjavik, Iceland Tuesday, June 24, 2025, 17:00 Hrs [IST] Alvotech, a global biot ...

AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF ...

The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF ...

Issue of Debt/BondStrong demand for Formycon 2025/2029 Bond leads to early closing of subscription period 24.06.2025 / 19:50 CET/CESTThe issuer is solely responsible for the content of this ...

About AVT06 (aflibercept) AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and ...